Clinical Policy: Anti-Migraine Agents
Reference Number: OH.PHAR.PPA.34
Effective Date: 01.01.2020
Last Review Date:
Line of Business: Medicaid

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

**CNS AGENTS: ANTI-MIGRAINE AGENTS – CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONIST**

<table>
<thead>
<tr>
<th>NO PA REQUIRED “PREFERRED”</th>
<th>PA REQUIRED “NON-PREFERRED”</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Trials of at least 3 controller medications)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular Agents: Beta-blockers</td>
<td>AIMOVIG™ (erenumab-aooe)†</td>
</tr>
<tr>
<td>CNS Agents: Anticonvulsant</td>
<td>EMGALITY™ (galcanezumab)</td>
</tr>
<tr>
<td>CNS Agents: Tricyclic antidepressants</td>
<td>AJOVY™ (fremanezumab-vfrm)*</td>
</tr>
<tr>
<td>CNS Agents: Serotonin-norepinephrine</td>
<td></td>
</tr>
</tbody>
</table>

†Initial Dose is limited to 70mg once monthly; may request dose increase if 70mg fails to provide adequate relief over two consecutive months.

* 675mg doses (quarterly administration) will not be authorized until patient has demonstrated efficacy of medication for at least 90 days

**CNS AGENTS: ANTI-MIGRAINE AGENTS – SEROTONIN 5-HT1 RECEPTOR AGONISTS –“Fast” Onset**

<table>
<thead>
<tr>
<th>NO PA REQUIRED “PREFERRED”</th>
<th>PA REQUIRED “NON-PREFERRED”</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIZATRIPTAN tablets (generic of Maxalt®)</td>
<td>ALMOTRIPTAN (generic of Axert®)</td>
</tr>
<tr>
<td>RIZATRIPTAN ODT (generic of Maxalt-MLT®)</td>
<td>ONZETRA™ XSAIL™ (sumatriptan)</td>
</tr>
<tr>
<td>SUMATRIPTAN tablets, nasal spray, injection (generic of Imitrex®)</td>
<td>ELETRIPTAN (generic of Relpax®)</td>
</tr>
<tr>
<td></td>
<td>SUMAVEL DOSEPRO® (sumatriptan)</td>
</tr>
<tr>
<td></td>
<td>ZOLMITRIPTAN (generic of Zomig®)</td>
</tr>
<tr>
<td></td>
<td>ZOMIG® NASAL SPRAY (zolmitriptan)</td>
</tr>
<tr>
<td></td>
<td>ZECUITY® (sumatriptan)</td>
</tr>
</tbody>
</table>

**CNS AGENTS: ANTI-MIGRAINE AGENTS – SEROTONIN 5-HT1 RECEPTOR AGONIST/NSAID COMBINATION**

<table>
<thead>
<tr>
<th>NO PA REQUIRED “NON-PREFERRED”</th>
<th>PA REQUIRED “NON-PREFERRED”</th>
</tr>
</thead>
<tbody>
<tr>
<td>NARATRIPTAN (generic of Amerge®)</td>
<td>FROVA® (frovatriptan)</td>
</tr>
</tbody>
</table>
FDA Approved Indication(s)
- Aimovig and Ajovy are indicated for the preventive treatment of migraine in adults
- Emgality is indicated for the preventive treatment of migraine and treatment of episodic cluster headaches in adults
- Triptans are indicated for the acute treatment of migraine attacks with or without aura in:
  - Adults (all products)
  - Pediatric patients (certain products only):
    - Axert: age 12 to 17 years with a history of migraine attacks usually lasting 4 hours or more (when untreated)
    - Maxalt, Maxalt MLT: age 6 to 17 years old
    - Treximet, Zomig Nasal Spray: age 12 to 17 years
- Imitrex injection and Sumavel DosePro are additionally indicated for the treatment of acute treatment of cluster headache in adults.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that the medications listed in the above tables are medically necessary when the following criteria are met:

I. Initial Approval Criteria
   A. Migraine headaches (must meet all):
      1. Member has had a failure of a therapeutic trial of at least two weeks with at least two medications not requiring prior approval unless one of the following:
         a. Allergy to preferred medications
         b. Contraindication to all preferred medications
         c. History of unacceptable/toxic side effects to at least two preferred medications
      2. If requested medication is Aimovig, Emgality or Ajovy all of the following must be met:
         a. Diagnosis of chronic or episodic migraine;
         b. 15 or more headaches per 30 days measured over 90 consecutive days and headache duration of longer than 4 hours per day or longer during an attack on average.
         c. Medication must be initiated by a neurologist
         d. Age ≥ 18 years;
         e. Member must have had failure of or contraindication to at least three other controller migraine medications for at least 30 days within the last 120 days (i.e., beta-blockers, neuroleptics, tricyclic antidepressants, and/or serotonin-norepinephrine)
         f. If request is for re-authorization there must be evidence of improved headache
control and medication is being prescribed by or in consultation with a neurologist. **May approve for 12 months**

**Approval duration: 180 days**

### B. Cluster headaches (must meet all)

1. Diagnosis of episodic cluster headaches;
2. Age ≥ 18 years;
3. At least 5 attacks within 30 days
4. Attacks characterized by severe or very severe unilateral orbital, supraorbital and/or temporal pain lasting 15 to 180 minutes when untreated; during part (but less than half) of the time-course of cluster headache, attacks may be less severe and/or of shorter or longer duration;
5. Either or both of the following:
   a. At least one of the following symptoms or signs ipsilateral to the headache:
      i. Conjunctival injection and/or lacrimation
      ii. Nasal congestion and/or rhinorrhea
      iii. Eyelid edema
      iv. Forehead and facial sweating
      v. Miosis and/or ptosis
   b. A sense of restlessness or agitation
6. Attacks have a frequency between one every other day and eight per day; during part (but less than half) of the active time-course of cluster headache, attacks may be less frequent;
7. Not better accounted for by another ICD-10 diagnosis;
8. In addition, to be considered episodic cluster headaches (a and b):
   a. Attacks fulfilling criteria for cluster headache (above) and occurring in bouts (cluster periods)
   b. At least two cluster periods lasting from seven days to one year (when untreated) and separated by pain-free remission periods of 90 days or more
9. Failure or intolerance of the following preventative therapy:
   a. Verapamil titrated at least to a dose of 480 mg daily (may need to be combined with glucocorticoids as adjunctive therapy for more rapid relief until verapamil is titrated)
10. If the requested medication is Emgality and the request is for **re-authorization** there must be evidence of improved headache control and medication is being prescribed by or in consultation with a neurologist. **May approve for 12 months**

**Approval duration: 180 days**

### II. Diagnoses/Indications for which coverage is NOT authorized:

#### A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.PMN.53 for Medicaid or evidence of coverage documents.
III. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration
CGRP: calcitonin gene-related peptide

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dosing Regimen</th>
<th>Dose Limit/Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular Agents: Beta-blockers</td>
<td>Migraine prophylaxis</td>
<td>Refer to prescribing information or Micromedex</td>
</tr>
<tr>
<td></td>
<td>Refer to prescribing information or Micromedex</td>
<td></td>
</tr>
<tr>
<td>CNS Agents: Anticonvulsants</td>
<td>Migraine prophylaxis</td>
<td>Refer to prescribing information or Micromedex</td>
</tr>
<tr>
<td></td>
<td>Refer to prescribing information or Micromedex</td>
<td></td>
</tr>
<tr>
<td>CNS Agents: Tricyclic antidepressants</td>
<td>Migraine prophylaxis</td>
<td>Refer to prescribing information or Micromedex</td>
</tr>
<tr>
<td></td>
<td>Refer to prescribing information or Micromedex</td>
<td></td>
</tr>
<tr>
<td>CNS Agents: Serotonin-norepinephrine</td>
<td>Migraine prophylaxis</td>
<td>Refer to prescribing information or Micromedex</td>
</tr>
<tr>
<td></td>
<td>Refer to prescribing information or Micromedex</td>
<td></td>
</tr>
<tr>
<td>Triptans</td>
<td>Migraine prophylaxis or episodic cluster headache (immitrex injection, Sumavel Dosepro®)</td>
<td>Refer to prescribing information or Micromedex</td>
</tr>
<tr>
<td></td>
<td>Refer to prescribing information or Micromedex</td>
<td></td>
</tr>
</tbody>
</table>

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications
• Contraindication(s):
  o Hypersensitivity
  o All triptans:
- History of coronary artery disease or coronary vasospasm; symptomatic Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders; history of stroke, transient ischemic attack, or hemiplegic or basilar migraine, or peripheral vascular disease; ischemic bowel disease; or uncontrolled hypertension.

- Recent (within 24 hours) used of another 5-HT1 agonist (e.g., another triptan), or an ergotamine-containing medication.

  - Relpax: within at least 72 hours of treatment with the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir or nelfinavir.
  - Imitrex, Zomig: use concurrently or within 2 weeks of discontinuation of an MAO-A inhibitor or non-selective MAO inhibitor.

- Boxed warning(s):
  - Treximet: risk of serious cardiovascular and gastrointestinal events
  - All other triptans: none reported

IV. Dosage and Administration
   A. Varies by drug product. See FDA approved dosing and administration.

V. Product Availability
   A. Varies by drug product. Refer to Clinical Pharmacology or other appropriate clinical resource for product availability.

VI. References
   Refer to package insert

<table>
<thead>
<tr>
<th>Reviews, Revisions, and Approvals</th>
<th>Date</th>
<th>P&amp;T Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy created</td>
<td></td>
<td>11.2019</td>
</tr>
</tbody>
</table>

Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical
practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2019 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed,